RxDoctor Payments Data

Benjamin Collie, MD

Internal Medicine · Carbondale, ILNPI 1689029654

Payments from drug & device makers

$1,558in general payments, 2019–2025

Across 97 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$395
  • AbbVie$266
  • AstraZeneca$156
  • GSK$133
  • Dexcom, Inc.$128
  • Mylan Specialty L.p.$78
  • plus $402 from 12 others

What the payments were for

  • Food & beverage$1,558100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,558 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$416
Medicare patients
14
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban215$210,959
OzempicSemaglutide126$160,260
JardianceEmpagliflozin113$154,425
JanuviaSitagliptin Phosphate80$76,876
TrulicityDulaglutide38$56,898
TradjentaLinagliptin57$48,642
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$44,960
XareltoRivaroxaban34$38,466
FarxigaDapagliflozin Propanediol45$33,806
MounjaroTirzepatide24$24,328
Breo ElliptaFluticasone/Vilanterol34$23,071
Repatha SyringeEvolocumab36$21,307
MyrbetriqMirabegron63$15,897
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,013
VascepaIcosapent Ethyl13$7,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$210,959215 claims
Novo NordiskOzempic$395$160,260126 claims
Lilly USA, LLCTrulicity, Mounjaro$32$81,22662 claims
GSKTrelegy Ellipta, Breo Ellipta$133$68,03196 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$156$51,43482 claims
Johnson & JohnsonXarelto$27$38,46634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Carbondale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →